Chiasma Inc. (CHMA) Rating Lowered to Sell at Zacks Investment Research
Chiasma Inc. (NASDAQ:CHMA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “
Shares of Chiasma (NASDAQ:CHMA) traded down 2.60% during trading on Tuesday, hitting $3.00. 146,267 shares of the company were exchanged. The firm’s 50-day moving average price is $2.76 and its 200 day moving average price is $3.70. Chiasma has a 12 month low of $2.40 and a 12 month high of $24.78. The firm’s market capitalization is $73.07 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/chiasma-inc-chma-rating-lowered-to-sell-at-zacks-investment-research.html
Chiasma (NASDAQ:CHMA) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.47. On average, equities research analysts expect that Chiasma will post ($3.14) earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. raised its position in Chiasma by 32.5% in the first quarter. Franklin Resources Inc. now owns 807,440 shares of the company’s stock worth $7,396,000 after buying an additional 198,200 shares in the last quarter. Geode Capital Management LLC raised its position in Chiasma by 19.4% in the first quarter. Geode Capital Management LLC now owns 55,693 shares of the company’s stock worth $510,000 after buying an additional 9,038 shares in the last quarter. Wellington Management Group LLP raised its position in Chiasma by 1,074.0% in the first quarter. Wellington Management Group LLP now owns 1,245,265 shares of the company’s stock worth $11,406,000 after buying an additional 1,139,195 shares in the last quarter. Sphera Funds Management LTD. acquired a new position in Chiasma during the first quarter worth about $2,113,000. Finally, Opaleye Management Inc. acquired a new position in Chiasma during the first quarter worth about $183,000. 58.76% of the stock is owned by institutional investors.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.